CoChat
Sign Up
Cited by 580Nanoparticle-Based Drug DeliveryRNA Interference and Gene DeliveryUltrasound and Hyperthermia Applications

The DOI matches its Crossref record; 260 of the 260 references it cites were found in a registry or an index.

Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release

Andresen, Thomas L., Jensen, Simon S., Jørgensen, Kent·2005·Progress in Lipid Research
DOI 10.1016/j.plipres.2004.12.001
Open this paper in CoChat — free account

Abstract

Tumor specific drug delivery has become increasingly interesting in cancer therapy, as the use of chemotherapeutics is often limited due to severe side effects. Conventional drug delivery systems have shown low efficiency and a continuous search for more advanced drug delivery principles is therefore of great importance. In the first part of this review, we present current strategies in the drug delivery field, focusing on site-specific triggered drug release from liposomes in cancerous tissue. Currently marketed drug delivery systems lack the ability to actively release the carried drug and rely on passive diffusion or slow non-specific degradation of the liposomal carrier. To obtain elevated tumor-to-normal tissue drug ratios, it is important to develop drug delivery strategies where the liposomal carriers are actively degraded specifically in the tumor tissue. Many promising strategies have emerged ranging from externally triggered light- and thermosensitive liposomes to receptor targeted, pH- and enzymatically triggered liposomes relying on an endogenous trigger mechanism in the cancerous tissue. However, even though several of these strategies were introduced three decades ago, none of them have yet led to marketed drugs and are still far from achieving this goal. The most advanced and prospective technologies are probably the prodrug strategies where non-toxic drugs are carried and activated specifically in the malignant tissue by overexpressed enzymes. In the second part of this paper, we review our own work, exploiting secretory phospholipase A2 as a site-specific trigger and prodrug activator in cancer therapy. We present novel prodrug lipids together with biophysical investigations of liposome systems, constituted by these new lipids and demonstrate their degradability by secretory phospholipase A2. We furthermore give examples of the biological performance of the enzymatically degradable liposomes as advanced drug delivery systems.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.plipres.2004.12.001

Cites

260 of 260 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 260 references

Research works printed but not linked: 34

  1. Juliano, 1976, Prog Clin Biol Res, 9, 21
  2. Senior, 1987, Crit Rev Ther Drug Carrier Syst, 3, 123
  3. Drummond, 1999, Pharmacol Rev, 51, 691
  4. Maeda, 1989, Crit Rev Ther Drug Carrier Syst, 6, 193
  5. Seymour, 1992, Crit Rev Ther Drug Carrier Syst, 9, 135
  6. Yuan, 1994, Cancer Res, 54, 3352
  7. Yuan, 1995, Cancer Res, 55, 3752
  8. Dellian, 1996, Am J Pathol, 149, 59
  9. Harrington, 2000, Clin Oncol, 12, 16
  10. Ellerhorst, 1999, Oncol Rep, 6, 1097
  11. Gabizon, 2001, Clin Cancer Res, 7, 223
  12. Gabizon, 1994, Cancer Res, 54, 987
  13. Ehrlich, 1913, Lancet, 2, 445
  14. Goren, 2000, Clin Cancer Res, 6, 1949
  15. Park, 2002, Clin Cancer Res, 8, 1172
  16. Venugopalan, 2002, Pharmazie, 57, 659
  17. Kong, 2000, Cancer Res, 60, 6950
  18. Huang, 1992, Cancer Res, 52, 6774
  19. Helmlinger, 2002, Clin Cancer Res, 8, 1284
  20. Huang, 1983, J Biol Chem, 258, 4034
  21. Bisby, 2000, Photochem Photobiol, 72, 57, 10.1562/0031-8655(2000)072<0057:AUODIP>2.0.CO;2 · DOI
  22. Song, 1984, Cancer Res, 44, 4721
  23. Dewhirst, 1997, Semin Oncol, 24, 616
  24. Needham, 2000, Cancer Res, 60, 1197
  25. Andresen, 2002, Biophys J, 82, 148A
  26. Uhl, 1997, vol. 24
  27. Graff, 2001, Clin Cancer Res, 7, 3857
  28. Kennedy, 1998, Cancer Res, 58, 500
  29. Ahmad, 1997, Cancer Res, 57, 1915
  30. Colbern, 1998, Clin Cancer Res, 4, 3077
  31. Cabanes, 1998, Clin Cancer Res, 4, 499
  32. Williams, 1993, Cancer Res, 53, 3964
  33. Harrington, 2001, Clin Cancer Res, 7, 243
  34. Allen, 1992, Cancer Res, 52, 2431

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Andresen, T. L., Jensen, S. S., & Jørgensen, K.
Affiliations
Technical University of Denmark (DK)
Corresponding author
Andresen, Thomas L.
ORCID
Andresen, Thomas L.
Venue
Progress in Lipid Research
Publisher
Elsevier BV
Published
2005-01
Volume
44
Issue
1
Pages
68-97
ISSN
0163-7827 (ISSN-L)
DOI
10.1016/j.plipres.2004.12.001
OpenAlex
W2065946609
Cited by
580
References
260
Citations by year
2026: 3 · 2025: 12 · 2024: 14 · 2023: 16 · 2022: 10 · 2021: 15 · 2020: 21 · 2019: 22 · 2018: 25 · 2017: 46 · 2016: 42 · 2015: 46 · 2014: 37 · 2013: 32 · 2012: 43
FWCI
1.81
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Progress in Lipid Research (publishedVersion)
  • PubMed (publishedVersion)
  • Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
Keywords
liposomal drug delivery, tumor-specific drug release, triggered drug release, secretory phospholipase A2, thermosensitive liposomes, cancer chemotherapy
MeSH terms
Antibodies, Antineoplastic Agents, Carrier Proteins, Cells, Hemolysis, Humans, Liposomes, Neoplasms, Phospholipases A, Prodrugs, Receptors, Cell Surface, Integrins, Drug Delivery Systems, Lipid Metabolism, Phospholipases A2, Folate Receptors, GPI-Anchored

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review